GO:0038110 interleukin-2-mediated signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0038110 describes the molecular signaling cascade triggered when interleukin-2 (IL-2) binds its receptor on the cell surface, leading to regulation of downstream cellular processes such as transcription.
• The pathway is critical for T-cell proliferation, survival, and effector function, and it involves key kinases JAK1 and JAK3, which are differentially regulated by tyrosine phosphorylation.
• IL-2 signaling engages multiple downstream modules including PI3K/Akt, NF-κB, and MAPK, and can be modulated by accessory proteins such as Annexin A6 and PTEN.
• Dysregulation of IL-2-mediated signaling is implicated in autoimmune diseases, immunodeficiency, and cancer, where it influences antitumor CD8+ cytotoxic T-cell responses.
• Studying this pathway requires integrated approaches including phosphoproteomics, CRISPR knockout screens, and functional assays to dissect gene-specific contributions.
• EDITGENE provides custom CRISPR cell models and library screening services to accelerate research on IL-2 signaling components and their disease relevance.
Description
The interleukin-2-mediated signaling pathway (GO:0038110) is a fundamental biological process that translates extracellular IL-2 cues into changes in gene expression, cell proliferation, and survival. IL-2 is a cytokine produced primarily by activated T cells, and its binding to the IL-2 receptor (IL-2R) initiates a cascade of phosphorylation events that are essential for immune homeostasis. This pathway is a paradigm for cytokine receptor signaling and has been a focus of immunology research for decades. Understanding its molecular players and regulatory mechanisms is critical for developing therapies that modulate immune responses in cancer, autoimmunity, and infectious diseases. The pathway is defined in the Gene Ontology as the series of molecular signals initiated by interleukin-2 binding to its receptor on the surface of a cell, and ending with the regulation of a downstream cellular process, e.g. transcription. This article synthesizes current knowledge on the components, mechanisms, and research methodologies associated with GO:0038110, drawing on verified literature to provide a comprehensive resource for researchers.
interleukin-2-mediated signaling pathway At A Glance
| GO ID | GO:0038110 |
|---|---|
| GO term | interleukin-2-mediated signaling pathway |
| Ontology | biological_process |
| Synonym | IL-2-mediated signaling pathway, interleukin-2-mediated signalling pathway |
| Major function | Transduces IL-2 signals from the cell surface to the nucleus, regulating transcription, proliferation, and survival. |
| Key kinases | JAK1 and JAK3 are differentially regulated by tyrosine phosphorylation. |
| Downstream effectors | PI3K/Akt, NF-κB, and diacylglycerol kinase are activated. |
| Regulatory proteins | Annexin A6 and PTEN modulate the pathway. |
| Disease relevance | Implicated in cancer, autoimmunity, and immune deficiencies. |
What Is GO:0038110?
GO:0038110, the interleukin-2-mediated signaling pathway, refers to the entire set of molecular events that occur after IL-2 binds to its receptor on the cell surface, culminating in the regulation of downstream cellular processes such as transcription. This includes receptor activation, recruitment and activation of Janus kinases (JAK1 and JAK3), phosphorylation of downstream substrates, and activation of signaling modules like PI3K/Akt and NF-κB. The pathway is synonymous with IL-2-mediated signaling pathway and interleukin-2-mediated signalling pathway.
Why Is interleukin-2-mediated signaling pathway Important in Cell Biology?
The interleukin-2-mediated signaling pathway is central to immune regulation, controlling T-cell expansion, effector differentiation, and memory formation. Its precise tuning is essential for mounting effective immune responses against pathogens and tumors while preventing autoimmunity. Moreover, IL-2 signaling is exploited in immunotherapy, such as high-dose IL-2 for metastatic melanoma and renal cell carcinoma, and is targeted by immunosuppressants. Understanding the molecular details of this pathway provides opportunities for therapeutic intervention and for interpreting genetic variants associated with immune disorders.
• Controls T-cell proliferation and survival, which are fundamental for adaptive immunity.
• Regulates interferon gamma production through NF-κB-dependent mRNA splicing.
• Activates PI3K/Akt pathway to promote cell survival and metabolism.
• Involves JAK1 and JAK3, mutations in which cause severe combined immunodeficiency.
• Modulated by PTEN and zinc ions, linking nutrient status to immune signaling.
• Annexin A6 regulates IL-2-mediated T-cell proliferation, highlighting membrane dynamics.
• Dysregulation contributes to autoimmune diseases and leukemia.
• IL-2 signaling in myelin suggests roles beyond the immune system.
• Target for cancer immunotherapy and vaccine adjuvants.
• Provides a model for understanding cytokine receptor signaling paradigms.
What Happens During interleukin-2-mediated signaling pathway?
IL-2 Binding and Receptor Activation
In simple terms: IL-2 docks onto its receptor on the cell surface, switching it on.
The pathway begins when interleukin-2 binds to the IL-2 receptor complex, which consists of alpha, beta, and gamma chains. This binding induces conformational changes that bring JAK1 and JAK3 into proximity, allowing them to phosphorylate each other and the receptor cytoplasmic domains. This initial activation is a prerequisite for all downstream signaling.
JAK-Mediated Phosphorylation and STAT Activation
In simple terms: The activated JAKs add phosphate tags to other proteins, including STATs, which then move to the nucleus to turn on genes.
JAK1 and JAK3 are differentially regulated by tyrosine phosphorylation, and their activation leads to phosphorylation of STAT5 and other substrates. Phosphorylated STATs dimerize and translocate to the nucleus to regulate transcription of target genes involved in proliferation and survival. This step is a key node for signal amplification.
PI3K/Akt Pathway Activation
In simple terms: A second signaling route through PI3K and Akt helps cells survive and grow.
IL-2 receptor engagement also activates phosphatidylinositol 3-kinase (PI3K), which generates PIP3 and recruits Akt to the membrane. Akt phosphorylation promotes cell survival and metabolism. This pathway is modulated by PTEN, a lipid phosphatase, and can be influenced by zinc ions that inhibit PTEN. Additionally, diacylglycerol kinase is activated in myelin, suggesting tissue-specific signaling.
NF-κB Activation and mRNA Splicing
In simple terms: IL-2 signaling can also turn on NF-κB, which controls the splicing of interferon gamma mRNA.
Recent work shows that IL-2-mediated NF-κB activation modulates mRNA splicing of interferon gamma, thereby affecting protein production. This adds a layer of post-transcriptional regulation to the pathway, linking cytokine signaling to the quality and quantity of immune effector molecules.
Modulation by Accessory Proteins
In simple terms: Other proteins like Annexin A6 can tweak the signal strength.
Annexin A6 regulates IL-2-mediated T-cell proliferation, likely by affecting membrane organization and signaling complex assembly. Such accessory proteins provide additional control points and may explain cell-type-specific responses.
Key Genes Involved in GO:0038110 interleukin-2-mediated signaling pathway
The following genes and proteins are core components or regulators of the interleukin-2-mediated signaling pathway, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL2 | Ligand that initiates signaling | Knockout models show immune dysregulation. |
| IL2RA | Alpha chain of IL-2 receptor, affinity modulation | Target in autoimmune diseases and cancer. |
| IL2RB | Beta chain, recruits JAK1 | Mutations linked to immunodeficiency. |
| IL2RG | Common gamma chain, recruits JAK3 | Defects cause X-linked SCID. |
| JAK1 | Tyrosine kinase, phosphorylates STATs | Differentially regulated by phosphorylation. |
| JAK3 | Tyrosine kinase, partners with JAK1 | Mutations cause autosomal SCID. |
| STAT5A | Transcription factor downstream of JAKs | Mediates proliferation and survival. |
| STAT5B | Transcription factor, similar to STAT5A | Redundant and specific roles. |
| PIK3CA | Catalytic subunit of PI3K | Activates Akt survival pathway. |
| PIK3R1 | Regulatory subunit of PI3K | Modulates PI3K activity. |
| AKT1 | Serine/threonine kinase, promotes survival | Phosphorylated upon IL-2 stimulation. |
| PTEN | Lipid phosphatase, negative regulator of PI3K | Inhibited by zinc, affecting Akt. |
| ANXA6 | Annexin A6, regulates membrane signaling | Modulates T-cell proliferation. |
| DGKQ | Diacylglycerol kinase, activated in myelin | Linked to IL-2 signaling in neural tissue. |
| NFKB1 | NF-κB subunit, regulates transcription and splicing | Mediates IL-2-induced IFN gamma splicing. |
| RELA | NF-κB subunit, partner of NFKB1 | Involved in NF-κB-dependent splicing. |
| CD3E | T-cell receptor component, uncoupled by IL-2 | IL-2 uncouples TCR from CD3 signaling. |
How Is interleukin-2-mediated signaling pathway Regulated?
The interleukin-2-mediated signaling pathway is tightly regulated at multiple levels. JAK1 and JAK3 activity is controlled by tyrosine phosphorylation and dephosphorylation cycles. PTEN acts as a negative regulator of PI3K/Akt signaling, and its inhibition by zinc ions augments Akt phosphorylation. Annexin A6 modulates T-cell proliferation, likely by affecting membrane dynamics and receptor clustering. Additionally, IL-2 signaling can uncouple the T-cell receptor from CD3, providing a feedback mechanism to limit TCR signaling. NF-κB-dependent mRNA splicing adds another layer of regulation, controlling interferon gamma production. These regulatory mechanisms ensure appropriate immune responses and prevent excessive activation.
interleukin-2-mediated signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| JAK3 | Severe combined immunodeficiency (SCID) | Knockout mice or patient-derived iPSCs |
| IL2RG | X-linked SCID | Knockout cell lines and organoids |
| PTEN | Cancer predisposition, autoimmunity | Point mutation knock-in for zinc-binding site |
| ANXA6 | T-cell proliferation defects | Overexpression and knockout T cells |
| MIR183/96/182 | Lung cancer progression | Knockout and overexpression in cancer cell lines |
Immunodeficiency and Autoimmunity
Mutations in JAK3 or IL2RG cause severe combined immunodeficiency (SCID), characterized by absent T and NK cells, highlighting the non-redundant role of IL-2 signaling in lymphocyte development. Conversely, dysregulated IL-2 signaling contributes to autoimmune diseases such as type 1 diabetes and rheumatoid arthritis, where excessive T-cell activation occurs.
Cancer and Immunotherapy
IL-2-mediated signaling is critical for antitumor CD8+ cytotoxic T-cell responses. The microRNA-183/96/182 cluster inhibits lung cancer progression by inducing an IL-2-mediated antitumor T-cell response, suggesting therapeutic potential. High-dose IL-2 is approved for metastatic melanoma and renal cell carcinoma, but toxicity limits its use.
Neurological Implications
IL-2 receptors and signaling components are present in myelin, where they activate diacylglycerol kinase and PI3K, suggesting roles in oligodendrocyte function and potential involvement in demyelinating diseases.
From interleukin-2-mediated signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does JAK1 phosphorylation site mutation affect downstream STAT activation? | Point mutation knock-in of JAK1 tyrosine residues |
| What is the role of Annexin A6 in IL-2-driven proliferation? | ANXA6 knockout and overexpression T-cell lines |
| Can PTEN inhibition by zinc modulate IL-2 signaling? | PTEN point mutation (catalytic dead) knock-in |
| How does IL-2 signaling affect IFN gamma splicing? | NFKB1 knockout with splicing reporter |
| Is IL2RA required for Treg vs effector T-cell responses? | Conditional IL2RA knockout mice |
| Can CRISPR activation of IL2 enhance antitumor immunity? | Overexpression via CRISPRa in CAR-T cells |
How to Study the interleukin-2-mediated signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Phosphoproteomics | Global tyrosine phosphorylation changes | Identify JAK/STAT substrates |
| RNA-seq | Transcriptome and splicing changes | Detect NF-κB-dependent splicing |
| CRISPR knockout screen | Gene essentiality for IL-2 responses | Discover novel regulators |
| Flow cytometry | STAT5 phosphorylation, proliferation | Validate pathway activation |
| Immunoblotting | Protein phosphorylation and expression | Confirm Akt and JAK activation |
| ELISA | Cytokine production (e.g., IFN gamma) | Measure functional output |
| Proximity ligation assay | Protein-protein interactions | Visualize receptor complex assembly |
| Live-cell imaging | Membrane dynamics and signaling | Study Annexin A6 role |
Phosphoproteomics
Mass spectrometry-based phosphoproteomics allows global profiling of tyrosine phosphorylation events after IL-2 stimulation, identifying JAK1 and JAK3 substrates and their differential regulation.
Transcriptomics and Splicing Analysis
RNA-seq and isoform-specific analysis can reveal changes in gene expression and alternative splicing, such as NF-κB-dependent IFN gamma splicing.
CRISPR Screens
Genome-wide CRISPR knockout screens can identify genes that modulate IL-2 signaling, proliferation, or survival, uncovering novel regulators like Annexin A6.
Functional Assays
Proliferation assays, flow cytometry for STAT5 phosphorylation, and cytokine production assays are standard for validating pathway activity.
How CRISPR Can Be Used to Study GO:0038110 interleukin-2-mediated signaling pathway
Knockout
CRISPR knockout of JAK1, JAK3, or IL2RG can abolish IL-2 signaling, providing clean models to study pathway dependence and identify compensatory mechanisms. Knockout of ANXA6 reduces T-cell proliferation, confirming its role.
Point Mutation
Introducing point mutations in JAK1 or JAK3 phosphorylation sites can dissect their differential regulation and downstream effects. Similarly, mutating PTEN's catalytic site can mimic zinc inhibition and enhance Akt phosphorylation.
Knock-in
Knock-in of tagged IL2RA or IL2RB allows tracking receptor trafficking and interactome dynamics. Knock-in of fluorescent reporters for STAT5 activation enables live-cell monitoring of signaling kinetics.
Overexpression
Overexpression of constitutively active Akt or STAT5 can bypass receptor requirements and study downstream effects. Overexpression of Annexin A6 can enhance or disrupt signaling depending on context.
How EDITGENE Supports interleukin-2-mediated signaling pathway Research
Researchers studying interleukin-2-mediated signaling pathway-related genes often need to determine whether a candidate gene is causally involved in pathway activation, regulation, or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling functional validation and drug discovery.
Contact EDITGENE today to design your custom CRISPR model for interleukin-2-mediated signaling pathway research.
Frequently Asked Questions About interleukin-2-mediated signaling pathway
What is the interleukin-2-mediated signaling pathway?
It is the series of molecular signals initiated by IL-2 binding to its receptor, leading to regulation of downstream processes such as transcription (GO:0038110).
What genes are involved in interleukin-2-mediated signaling?
Key genes include IL2, IL2RA, IL2RB, IL2RG, JAK1, JAK3, STAT5A, STAT5B, PI3K, AKT1, PTEN, and ANXA6.
How does IL-2 signaling activate T cells?
IL-2 binding triggers JAK1/JAK3 phosphorylation, STAT5 activation, and PI3K/Akt signaling, driving proliferation and effector functions.
What diseases are associated with defects in IL-2 signaling?
Mutations cause severe combined immunodeficiency, and dysregulation is linked to autoimmunity and cancer.
What is the role of JAK3 in IL-2 signaling?
JAK3 is a tyrosine kinase that partners with JAK1 to phosphorylate STATs; its deficiency causes SCID.
How is IL-2 signaling regulated?
It is regulated by phosphorylation/dephosphorylation, PTEN, Annexin A6, and NF-κB-dependent splicing.
Can CRISPR be used to study IL-2 signaling?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect gene function in this pathway.
What is the role of PTEN in IL-2 signaling?
PTEN negatively regulates PI3K/Akt; its inhibition by zinc augments IL-2-mediated Akt phosphorylation.
How does Annexin A6 affect IL-2 signaling?
Annexin A6 regulates IL-2-mediated T-cell proliferation, likely by modulating membrane signaling complexes.
What experimental methods are used to study IL-2 signaling?
Common methods include phosphoproteomics, RNA-seq, CRISPR screens, flow cytometry, and immunoblotting.
Conclusion
The interleukin-2-mediated signaling pathway (GO:0038110) is a central axis of immune regulation with profound implications for health and disease. Its molecular components, from JAK kinases to PI3K/Akt and NF-κB, offer numerous targets for therapeutic intervention and research. By leveraging advanced CRISPR models and multi-omics approaches, researchers can continue to unravel the complexities of this pathway and translate findings into clinical advances.
References
- 1. Van Gelder RD et al.. 2025. Interleukin-2-mediated NF-κB-dependent mRNA splicing modulates interferon gamma protein production.. EMBO Rep 26(1):16-35 PMID: 39578552
- 2. Haughn L et al.. 1998. Interleukin 2-mediated uncoupling of T cell receptor alpha/beta from CD3 signaling.. J Exp Med 188(9):1575-86 PMID: 9802969
- 3. Chakraborty G et al.. 2003. Interleukin-2 receptors and interleukin-2-mediated signaling in myelin: activation of diacylglycerol kinase and phosphatidylinositol 3-kinase.. Neuroscience 122(4):967-73 PMID: 14643763
- 4. Plum LM et al.. 2014. PTEN-inhibition by zinc ions augments interleukin-2-mediated Akt phosphorylation.. Metallomics 6(7):1277-87 PMID: 24759986
- 5. Cornely R et al.. 2016. Annexin A6 regulates interleukin-2-mediated T-cell proliferation.. Immunol Cell Biol 94(6):543-53 PMID: 26853809
- 6. González-García A et al.. 1997. Intermediate affinity interleukin-2 receptor mediates survival via a phosphatidylinositol 3-kinase-dependent pathway.. J Biol Chem 272(15):10220-6 PMID: 9092570
- 7. Liu KD et al.. 1997. Janus kinases in interleukin-2-mediated signaling: JAK1 and JAK3 are differentially regulated by tyrosine phosphorylation.. Curr Biol 7(11):817-26 PMID: 9382798
- 8. Kundu ST et al.. 2022. The microRNA-183/96/182 cluster inhibits lung cancer progression and metastasis by inducing an interleukin-2-mediated antitumor CD8(+) cytotoxic T-cell response.. Genes Dev 36(9-10):582-600 PMID: 35654454
